TIQUE proposes to generate a flexible and scalable value-based model of care, giving a holistic approach to treatments for patients with advanced heart failure. The model is designed from a vision of integrated care where patients' care needs are anticipated taking into account their expressed wills, thereby optimizing the quality of care and the use of clinical resources. In this model, community and informal carers are foreseen as actors in patient treatment and follow-up.

This model of care is extensive in its use of technology, using:

• disruptive solutions at home or in the normal environment of patients,
• data driven interventions,
• user friendly interfaces, and 
• interoperable and effective communication tools among carers to effectively integrate care and cure services.

Grounded in a combination of (1) technology, (2) integrated care and (3) a value-based model, TIQUE will push for a paradigm shift:

1.- TIQUE’s solutions aim to remove barriers in market development, such as barriers for services to integrate new technologies (devices and apps) available, because these are not connected, but are tipically standalone, isolated or disease specific...

2.- TIQUE is a predictive, preventive, personalised and participative integrated care model for advanced heart failure that delivers holistic care management engaging community resources..

3.- TIQUE is a value-based model on which business prototypes with a long-term vision can be built.

The three pillars are designed to warrant an innovative solution sustainable in the long-term.

One of the challenges of the project is to create holistic, and responsive technology solutions for early detection of exacerbations in patients’ conditions to avoid emergencies and hospital stays. TIQUE’s procurers encourage the market to propose innovative approaches to tackle this challenge.

Participation in the tendering process is open on equal terms to all types of operators from any country, regardless of their geographic location, size or governance structure. However, there is a requirement relating to the place where R&D services take place. At least 50% of the total value of activities covered by the framework agreement must be carried out in the EU Member States or H2020 associated countries. The principal R&D staff working on the PCP must be located in the EU Member States or H2020 associated countries.

In the case of the UK, scientists, researchers and businesses can continue to participate in Horizon 2020 as if the UK remained a member state for all H2020 projects (here).

AQuAS, TICSalut, ASSUTA MC, JERA and VALDE support the procurers in TIQUE’s PCP challenge definition and in the different phases of the PCP process, revising the documents and templates. Hospital de Sant Pau is the lead procurer and in charge of the e-tender platform and of the OMC process, with support from all partners.

You are invited to participate in the preparation of the tender document and in the OMC process launched in September 2021.

You can send us your proposals for participating in the OMC following this link to our website:

https://www.tiquepcp.eu/web/tique/international-omc-event

Yes, you can. The Open Market Consultation is not part of the selection or pre-qualification process of TIQUE’s PCP R&D providers. It is a previous step to canvass wide stakeholder opinion on the suitability of TIQUE’s PCP. Submitted questionnaires help procurers fine-tune the final requirements according to the market. So, whilst not compulsory, they  are much appreciated and highly advisable for suppliers.

With the market consultation, the consortium will inform the market about TIQUE’s PCP opportunities, explain in detail the PCP process and open a dialogue with potential suppliers and other specialists in the field about the scope of TIQUE with the aim of preparing an accurate future procurement.

The EU Guidance for PCP tender documents on how to prepare a Prior Information Notice for an Open Market Consultation clearly states that also during an Open Market Consultation, procurers should respect the equal treatment and transparency principles. In particular: “Procurers cannot, during an Open Market Consultations (including during face-to-face meetings, provide information to one potential tenderer without providing that same information to all other potential tenderers. Procurers should therefore publish all answers that they provided to questions from potential tenderers during the Open Market Consultation (e.g. in the form of a Q&A list). Please note that such Q&A should be anonymised (not mentioning the name of the tenderer who asked the question) and stripped of any references to confidential solutions/products of specific vendors (to respect the confidentiality/equal treatment principles)”.

Once the deadline for submitting unsolicited offers has been reached, the buyer’s group will compile the proposals submitted, as well as the other information gathered during the consultation and the pre-OMC informative events. If it is deemed necessary, it may request those who participated in the OMC to clarify some points. In addition, it reserves the right to convene individual participants individually to make a more detailed presentation or to expand information on their proposal.

We will be launching TIQUE’s PCP request for tenders June 2022.

The Request for Tenders (RFT) describes the specific PCP procedure with the aim of generating competing offers from different tenderers and to finally award R&D service contracts (Specific Contracts). The RFT will follow the European Commission H2020 model and will include an introduction on PCP, a description of the scope of the tender, a timetable and an explanation of the tendering procedure as well as the selection and award criteria. Furthermore, the RFT provides information on how to submit a tender, on the legal provisions foreseen and on the way tenders will be evaluated.

There will be a single call for procurement for phase I.

Those proposals awarded in Phase I will be the only eligible for the next phase. To sum it up, the PCP process has three Phases: I (solution design), II (prototype) and III (field-testing). To participate in phase II it is mandatory to have been awarded in phase I. To participate in phase III it is mandatory to have been awarded in phase II.

The total budget for TIQUE’s PCP 4.429.075 euros (including VAT).  This budget is reserved for procurement for phases 1 through 3. It does not cover the procurement of commercial volumes of the solutions.

It is possible, but if a participant receives funding from Horizon 2020 for a given activity, it is not allowed to finance that same activity with a different set of HORIZON 2020 financing.

The PCP is a tool for procurers to improve the solutions available in the market but they have no intention of holding the IPRs. However, preferential conditions should be offered to procurers.

According to the European Commission’s guide on PCP, each contractor will keep ownership of the IPRs attached to the results they generate during the PCP implementation. The tendered price is expected to take this into account.

The ownership of the IPRs will be subject to the following:

• the Buyers Group has the right to:

• access results, on a royalty-free basis, for their own use.
• grant (or require the contractors to grant) non-exclusive licences to third parties to exploit the results under fair and reasonable conditions (without the right to sub-license).

• The Buyers Group has the right to require the contractors to transfer ownership of the IPRs if the contractors fail to comply with their obligation to commercially exploit the results or use the results to the detriment of the public interest (including security interests).

Details will be included in the documentation requested for the tender.